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Abstract
Background: In the present study we analyze, in patients with breast cancer, the tumor expression of
androgen receptors (AR), its relationship with clinicopathological characteristics and with the expression
of several matrix metalloproteases (MMPs) and their inhibitors (TIMPs), as well as with prognosis.
Methods: An immunohistochemical study was performed using tissue microarrays and specific antibodies
against AR, MMPs -1, -2, -7, -9, -11, -13, -14, and TIMPs -1, -2 and -3. More than 2,800 determinations on
tumor specimens from 111 patients with primary invasive ductal carcinoma of the breast (52 with axillary
lymph node metastases and 59 without them) and controls were performed. Staining results were
categorized using a score based on the intensity of the staining and a specific software program calculated
the percentage of immunostained cells automatically.
Results: A total of 83 cases (74.8%) showed a positive immunostaining for AR, but with a wide variation
in the staining score values. There were no significant associations between the total immunostaining
scores for AR and any clinicopathological parameters. However, score values for MMP-1, -7 and -13, were
significantly higher in AR-positive tumors than in AR-negative tumors. Likewise, when we considered the
cellular type expressing each factor, we found that AR-positive tumors had a higher percentage of cases
positive for MMP-1, -7, -11, and TIMP-2 in their malignant cells, as well as for MMP-1 in intratumoral
fibroblasts. On the other hand, multivariate analysis demonstrated that patients with AR-positive tumors
have a significant longer overall survival than those with AR-negative breast carcinomas (p = 0.03).
Conclusion: Our results confirm that AR are commonly expressed in breast cancer, and are correlated
with the expression of some MMPs and TIMP-2. Although we found a specific value of AR expression to
be a prognostic indicator in breast cancer, the functional role of AR in these neoplasms is still unclear and
further data are needed in order to clarify their biological signification in breast cancer.
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In the last two decades, the molecular mechanisms related
to the hormone dependence of breast tumors have been
extensively investigated and the role of the estrogen and
progesterone receptors (ER and PgR) in promoting breast
cancer has been well documented. However, the role of
androgens and their receptors (AR) in breast cancer etiol-
ogy and progression has been less profoundly studied and
remains an unanswered question [1,2]. There is evidence
showing that androgens can directly stimulate the growth
of human breast cancer cell lines [3]. In addition, both ret-
rospective and prospective studies have reported statisti-
cally significant associations between increased levels of
testosterone and higher breast cancer risk in both pre- and
postmenopausal women [4-6]. Likewise, AR is expressed
in approximately 70% to 90% of invasive breast cancers,
a frequency comparable with or higher than the one
reported for ER (70–80%) and PgR (50–70%) [1,7-10].
Although a relationship between AR and both ER and PgR
status has been demonstrated [10-14], a significant per-
centage of tumors are positive for AR and negative for ER
and PgR [13]. This finding reveals the independent expres-
sion of AR in human breast cancer. However, there are
apparently divergent data on the biological and clinical
signification of AR in breast cancer. AR have also been
detected in a significantly higher percentage of AR-posi-
tive ductal carcinomas "in situ" (DCIS) adjacent to inva-
sive carcinomas of the breast than in pure DCIS lesions
[15], suggesting that AR correlates with tumor invasive-
ness, at least in the early phases of tumor progression. In
invasive breast carcinomas, AR-positive tumors have been
associated with a low or intermediate histological grade
(G1, G2) [10,13,14,16,17]. In addition, certain types of
breast carcinoma, even high grade ones, are typically ER-
and PR-negative, but AR-positive; a typical example of
such tumors is the apocrine breast carcinoma [18,19].
However, the expression level of both the AR gene and the
AR protein in breast cancer was found to be positively cor-
related with axillary lymph node involvement [20]. In
addition, it is remarkable that among the steroid hor-
mone receptors, the androgen receptor is the best pre-
served one during metastases development and is
expressed in the majority of metastatic tumors [8,21].
There is evidence as well indicating that AR/steroids are
able to up-regulate matrix metalloproteases (MMPs), con-
tributing to invasiveness via destruction of basement
membrane and extracellular matrix [22,23]. Nevertheless,
only a few studies have examined the impact of AR expres-
sion on patient prognosis in early breast cancer. Patients
with AR-positive tumors were shown to have a significant
trend toward longer relapse-free and/or overall survival in
the univariate analysis than those patients with AR-nega-
tive tumors [1,16,24], but none in the multivariate analy-
sis [1,16]. In addition, other studies have not found any
significance of AR expression in predicting prognosis in
breast cancer [20,25].
Since AR are expressed by an important percentage of
breast carcinomas and there are evidences pointing their
role in tumor progression, in the present study we analyze
the tumor expression of AR, its relationship with clinico-
pathological characteristics, with several MMPs and their
inhibitors (TIMPs) and with prognosis, in patients with
breast cancer.
Methods
Patient characteristics and tissue specimen handling
This study comprised 111 women with a histologically
confirmed diagnosis of breast cancer and treated between
1990 and 2001. We selected women with the following
inclusion criteria: invasive ductal carcinoma, at least ten
histopathologically-assessed axillary lymph nodes, and a
minimum of five years of follow-up in those women with-
out tumor recurrence. The exclusion criteria were the fol-
lowing: metastatic disease at presentation, prior history of
any type of malignant tumor, bilateral breast cancer at
presentation, having received any type of neoadjuvant
therapy, development of loco-regional recurrence during
the follow-up period, development of a second primary
cancer, and absence of sufficient tissue in the paraffin
blocks used for manufacturing the TMAs. From a total of
1053 patients fulfilling these criteria, we selected ran-
domly a sample size of 111 patients, in accordance to four
different groups of similar size and stratified with regard
to nodal status and the development of metastatic disease,
which were the key measure variables of this study. Thus,
we included an important number of events in both node-
negative and node-positive patients subgroups (half of the
cases with distant metastasis during the follow-up period
in each one of these subgroups) in order to warrant the
statistical power of the survival analysis. Patients charac-
teristics included in the two main groups, with or without
distant metastases, are listed in Table 1. Histological grade
was determined according to the criteria reported by
Elston and Ellis [26].
Women were treated according to the guidelines used in
our institution. The study adhered to national regulations
and was approved by our institution's Ethics and Investi-
gation Committee. The end-point was death from tumor
progression. The median follow-up period in patients
without metastases was of 87.5 months, and of 52.7
months in patients with them.
Tissue microarrays and immunohistochemistry
Routinely fixed (overnight in 10% buffered formalin),
paraffin-embedded tumor samples stored in our pathol-
ogy laboratory files were used in this study. Histopatho-
logically representative tumor areas were defined onPage 2 of 10
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BMC Cancer 2008, 8:149 http://www.biomedcentral.com/1471-2407/8/149Table 1: Relationship between AR expression and different clinicopathological parameters in 111 breast carcinomas.
Patient and tumor characteristics N Median (range) p N° positive cases (score >0) (%) p
Total cases 111 69 (0–288) 83 (74.8)
Age (years) n.s. n.s.
≤ 58 55 68(0–279) 44(80)
>58 56 76(0–288) 39(69.6)
Menopausal status n.s. n.s.
Premenopausal 29 92(0–279) 25(86.2)
Postmenopausal 82 59(2–288) 58(70.4)
Tumor size n.s. n.s.
T1 50 80(0–288) 40(80)
T2 61 64(0–279) 43(70.5)
Nodal status n.s. n.s.
Positive 52 53(0–273) 38(73.1)
Negative 59 100(0–288) 45(76.3)
Stage n.s. n.s.
I 32 71(0–273) 25 (78.1)
II 51 64(0–243) 40 (78.4)
III 28 83.5(0–288) 18 (64.3)
Histologic grade n.s. n.s.
Well Dif. 30 66.5(0–273) 22(73.3)
Mod. Dif. 57 88(0–288) 44(77.2)
Poorly Dif. 24 40.5(0–267) 17(70.8)
Estrogen receptor n.s. n.s.
Negative 52 55.5(0–273) 34(65.4)
Positive 59 80(0–288) 49(83.1)
Progesterone receptor n.s. n.s.
Negative 59 58(0–279) 41(69.5)
Positive 52 76(0–288) 42(80.8)
Desmoplastic reaction n.s. n.s.
No 35 48(0–270) 23(65.7)
Yes 76 80.5(0–288) 60(78.9)
Peritumoral inflammation n.s. n.s.
No 65 69.5(0–279) 48(75)
Yes 46 86(0–288) 34(75.6)
Tumor advancing edge n.s. n.s.Page 3 of 10
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the slides. Tumor tissue array blocks were obtained by
punching a tissue cylinder (core) with a diameter of 1.5
mm through a histologically representative area of each
'donor' tumor block, which was then inserted into an
empty 'recipient' tissue array paraffin block using a man-
ual tissue arrayer (Beecker Instruments, Sun Praerie, Win-
consin, USA) as described elsewhere [27]. Collection of
tissue cores was carried out under highly controlled con-
ditions. Areas of non-necrotic cancerous tissue were
selected for arraying by two experienced pathologists
(L.O. González and A. M. Merino). Two cores were
employed for each case. From the 111 tumor samples
available, three tissue array blocks were prepared, each
one containing 37 tumors samples, as well as internal
controls including four normal breast tissue samples from
two healthy women who had undergone reductive mam-
mary surgery.
Three composite high-density TMA blocks were designed,
and serial 5-µm sections were consecutively cut with a
microtome (Leica Microsystems GmbH, Wetzlar, Ger-
many) and transferred to adhesive-coated slides. One sec-
tion from each tissue array block was stained with H&E,
and these slides were then reviewed to confirm that the
sample was representative of the original tumor. Immu-
nohistochemistry was done on these sections of TMA
fixed in 10% buffered formalin and embedded in paraffin
using a TechMate TM50 autostainer (Dako, Glostrup,
Denmark). Antibodies for MMPs and TIMPs were
obtained from Neomarker (Lab Vision Corporation, Fre-
mont, CA, USA). The dilution for each antibody was
established based on negative and positive controls (1/50
for MMP-2, -7, 14, and TIMP-2; 1/100 for 9, 13, TIMP-1
and -3; 1/200 for MMP-1, MMP-11); and anti-AR clone
AR 441 (Dako) at a dilution of 1/50. The positive control
was prostate carcinoma, previously tested. The negative
control was DakoCytomation mouse serum diluted to the
same mouse IgG concentration as the primary antibody.
Tissue sections were deparaffinized in xylene, and then
rehydrated in graded concentrations of ethyl alcohol
(100%, 96%, 80%, 70%, then water). To enhance antigen
retrieval only for some antibodies, TMA sections were
microwave-treated (H2800 Microwave Processor,
EBSciences, East Granby, Connecticut, USA) in citrate
buffer pH 6 (Target Retrieval Solution, Dako) at 99°C for
15 min. Endogenous peroxidase activity was blocked by
incubating the slides in peroxidase-blocking solution
(Dako) for 5 min. The EnVision Detection Kit (Dako) was
used as the staining detection system. Sections were coun-
terstained with hematoxilin, dehydrated with ethanol,
and permanently coverslipped.
TMA analysis
For each antibody preparation studied, the location of
immunoreactivity, percentage of stained cells and inten-
sity were determined. All the cases were semiquantified
for each protein-stained area. An image analysis system
made up by the Olympus BX51 microscope and soft anal-
ysis (analySIS®, Soft imaging system, Münster, Germany)
was employed as follows: tumor sections were stained
with antibodies according to the method explained above
and counterstained with hematoxilin. There were differ-
ent optical thresholds for both stains. Each core was
scanned with a 400× power objective in two fields per
core. Fields were selected searching for the protein-stained
areas. The computer program selects and traces a line
around antibody-stained areas (higher optical threshold:
red spots), with the remaining, non-stained areas (hema-
toxilin-stained tissue with lower optical threshold) stand-
ing out as a blue background. Any field has an area ratio
of stained (red) versus non-stained areas (blue). A final
area ratio was obtained after averaging two fields. To eval-
uate immunostaining intensity we used a numeric score
ranging from 0 to 3, reflecting the intensity as follows: 0,
no staining; 1, weak staining; 2, moderate staining; and 3,
intense staining. Using an Excel spreadsheet, the mean
score was obtained by multiplying the intensity score (I)
by the percentage of stained cells (PC) and the results were
added together (total score: I × PC). This overall score was
then averaged with the number of cores that were done for
each patient. If there was no tumor in a particular core,
then no score was given. In addition, for each tumor, the
mean score of two core biopsies was calculated.
Furthermore, whole-tissue sections from tumor blocks
from a subset of ten cases were compared with the corre-
sponding TMA discs, regarding AR expression. These cases
were selected randomly, and the obtained clinicopatho-
logical data were very similar to those from the whole
series. Each whole-tissue section was scanned with a 400×
Expansive 49 50.5(0–270) 33(68.8)
Infiltrating 62 84.5(0–288) 48(80)
Vascular invasion n.s. n.s.
No 72 64.5(0–288) 52(72.2)
Yes 39 81(0–279) 31(79.5)
Table 1: Relationship between AR expression and different clinicopathological parameters in 111 breast carcinomas. (Continued)Page 4 of 10
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searching for the protein-stained areas, such as it was
described above. Previously, we described a similar vali-
dation study for the evaluated MMPs and TIMPs, in inva-
sive breast cancer [28].
Data analysis and statistical methods
Differences in percentages were calculated with the chi-
square test. Immunostaining score values for each protein
were expressed as median (range). Comparison of immu-
nostaining values between groups was made with the
Mann-Whitney or Kruskall-Wallis tests. For metastasis-
free survival analysis we used the Cox's univariate
method. Cox's regression model was used to examine
interactions of different prognostic factors in a multivari-
ate analysis. The SPSS 11.5 program was used for all cal-
culations.
Results
More than 2,800 determinations were performed on
TMAs of cancer specimens from 111 patients with primary
invasive ductal carcinoma of the breast and controls. Min-
imal internal variance of score data between duplicate tis-
sue cores from the same patients was detected in the tissue
arrays, showing a high agreement for each protein (r >
0.95 and p < 0.0001, for each protein). In the validation
study there was a total concordance in the global expres-
sion, as well as in the intensity of immunostaining for AR,
between TMA cases and the corresponding whole-tissue
sections. In addition, there were highly significant correla-
tions in the immunostaining scores between these two
paired sets (r > 0.90 and p < 0.0001, for each protein).
Figure 1 shows examples of tissue immunostained for the
proteins evaluated. As it was expected, AR immunostain-
ing was of nuclear localization. A total of 83 cases (74.8%)
showed a positive immunostaining for AR, although with
a wide variation in the immunostaining score values (Fig-
ure 2). There were only five cases with a score value of less
than ten points (three with a score of 5, and two with a
score of 8). Immunostaining for MMPs and TIMPs was
localized predominantly in the cytoplasm of the malig-
nant cells, but also in stromal cells in a considerable per-
centage of cases.
There were not any significant associations between the
total immunostaining scores for AR and clinicopatholog-
ical parameters such as tumor size, lymph node involve-
ment, stage, histological grade, high Nottingham
prognostic index, infiltrating edge, vascular invasion,
desmoplastic reaction or peritumoral inflammation, ER
or PgR status (Table 1).
In the present study we also investigated the possible rela-
tionship between AR expression and both MMPs and
TIMPs expression in tumors, which have been associated
with an aggressive behaviour and a poor prognosis in
breast cancer patients. Our data demonstrated some sig-
nificant associations. Thus, score values for MMP-1, -7
and -13, were significantly higher in AR-positive tumors
than in AR-negative tumors (Table 2). Likewise, when we
Microphotographs representative of malignant cells positive for AR (A), MMP-1 (B), MMP-7 (C), MMP-13 (D) and TIMP-2 (E) and fibroblasts ositive for MMP-1 (F)Figure 1
Microphotographs representative of malignant cells positive for AR (A), MMP-1 (B), MMP-7 (C), MMP-13 (D) 
and TIMP-2 (E) and fibroblasts positive for MMP-1 (F). Magnification 400×.Page 5 of 10
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found that the scores for AR were significantly higher in
malignant cells from tumors positive for MMP-1, -7, -11,
and TIMP-2, as well as for MMP-1 in intratumor fibrob-
lasts (Table 3). However, there was not any significant
association between MMPs or TIMPs expression by mono-
nuclear inflammatory cells and the AR status of the
tumors (Table 3).
We initially investigated the possible association between
each immunostaining score value for AR, as cut-off points,
and relapse-free survival. We found that none of these cut-
off points were significantly associated with relapse-free
survival in our patient population (data not shown).
However, our results demonstrated that when patients
were dichotomized in two different groups with regard to
the more optimal cut-off point of score values for AR
(score = 0 v.s. score > 0), patients with AR-positive tumors
had a significantly longer survival than patients with AR-
negative tumors (p = 0.01) (Figure 3), but there was no
difference regarding the occurrence of distant metastases
(data no shown). In addition, and in accordance with pre-
vious studies indicating the prognostic value of AR expres-
sion in ER-negative tumors, we investigated that value in
the subset of 59 ER-negative tumors included in the
present study, but we could not find any significant value
of AR expression able to predict either relapse-free or over-
all survival in the corresponding patients (data not
shown). Multivariate analysis according to Cox model
demonstrated that tumor stage (stage II: relative risk (RR)
(confidence interval): 3.46(1.11–10.78); stage III:
7.29(2.37–22.41); p < 0.001) and PgR status (positive:
0.19(0.08–0.49), p < 0.001) were significantly associated
with overall survival. Multivariate analysis also confirmed
that patients with AR-positive carcinomas had a signifi-
cant longer overall survival than those with AR-negative
breast neoplasms (AR-positive: 0.46(0.23–0.93), p =
0.03).
Discussion
Our results confirmed previous biochemical and immu-
nohistochemical studies indicating that AR are expressed
in a considerable proportion of breast carcinomas [1,7-
10]. We also found that AR expression in breast carcino-
mas is highly variable because of tumor heterogeneity. We
determined that there are some correlations between AR
and MMPs expression. However, AR expression was not
related with the occurrence of distant metastases, but
instead associated with a longer overall survival in breast
cancer patients.
Contrary to other studies, we found no significant differ-
ences between AR expression and the clinicopathological
characteristics of the tumors, such as histological grade
[10,13,14,16,17,29], axillary lymph node involvement
[20], ER or PgR status [10-14]. Nevertheless, we found a
positive and significant relationship between AR expres-
sion and the expression of parameters potentially indica-
tive of invasiveness, such as MMP-1, -7 and -13. This
association could be relevant because it is now known
that MMPs promote metastases not only by modulating
the remodelling of extracellular matrix, but because
MMPs are able to impact in vivo on tumor cell behaviour
as a consequence of their ability to cleave growth factors,
cell surface receptors, cell adhesion molecules, and chem-
okines/cytoquines [30-33]. Furthermore, by cleaving pro-
apoptotic factors, MMPs are able to produce a more
aggressive phenotype via generation of apoptotic resistant
cells [34]. MMPs may also regulate cancer-related angio-
genesis, both positively through their ability to mobilize
or activate pro-angiogenic factors [35], and negatively via
generation of angiogenesis inhibitors, such as angiostatin
and endostatin, cleaved from large protein precursors
[36]. In addition, it is now understood that TIMPs are
Distribution of AR score values in 111 breast carcinomasFigure 2
Distribution of AR score values in 111 breast carcino-
mas.
Table 2: Relationship between AR and MMPs and TIMPs 
expression in 111 breast carcinomas.
AR score values (median (range))
Factor AR negative AR positive p
MMP-1 117(0–285) 140(0–285) 0.01
MMP-2 0(0–136) 0(0–246) n.s.
MMP-7 65.1(0–267.5) 142(0–270) 0.002
MMP-9 62.5(0–176) 77(0–273) n.s.
MMP-11 150(0–279) 157.6(0–277.7) n.s.
MMP-13 52.8(0–234) 63(0–192.3) 0.04
MMP-14 83.8(0–254) 83(0–261) n.s.
TIMP-1 135(0–276) 140(0–285) n.s.
TIMP-2 104(0–243) 83(0–243) n.s.
TIMP-3 65.3(0–272.4) 116(0–271.3) n.s.Page 6 of 10
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Table 3: Relationship between the expression of AR, MMPs and TIMPs by each cellular type in breast cancer.
Factor N AR score values median (range) p value
MMP-1
TC (-) vs. (+) 7/104 0(0–70)/80(0–288) 0.004
FC (-) vs. (+) 14/97 2.5(0–225)/80(0–288) 0.03
MIC (-) vs. (+) 30/81 53(0–225)/81(0–288) n.s.
MMP-2
TC (-) vs. (+) 70/41 59.5(0–279)/90(0–288) n.s.
FC (-) vs. (+) 83/28 69(0–288)/88(0–270) n.s.
MIC (-) vs. (+) 108/3 68.5(0–288)/66(0–132) n.s.
MMP-7
TC (-) vs. (+) 8/103 0(0–156)/80(0–288) 0.01
FC (-) vs. (+) 27/84 68(0–267)/74.5(0–288) n.s.
MIC (-) vs. (+) 50/61 66(0–267)/81(0–288) n.s.
MMP-9
TC (-) vs. (+) 27/84 48(0–270)/80.5(0–288) n.s.
FC (-) vs. (+) 93/18 68(0–288)/83.5(0–270) n.s.
MIC (-) vs. (+) 98/13 80(0–279)/30(0–288) n.s.
MMP-11
TC (-) vs. (+) 11/100 8(0–168)/80(0–288) 0.03
FC (-) vs. (+) 33/78 53(0–264)/81(0–288) n.s.
MIC (-) vs. (+) 72/39 68(0–270)/87(0–288) n.s.
MMP-13
TC (-) vs. (+) 29/82 48(0–225)/74.5(0–288) n.s.
FC (-) vs. (+) 54/57 56(0–267)/81(0–288) n.s.
MIC (-) vs. (+) 70/41 64.5(0–279)/92(0–288) n.s.
MMP-14
TC (-) vs. (+) 10/101 64.5(0–273)/69(0–288) n.s.
FC (-) vs. (+) 21/90 92(0–273)/66.5(0–288) n.s.
MIC (-) vs. (+) 50/61 64.5(0–273)/81(0–288) n.s.
TIMP-1
TC (-) vs. (+) 6/105 0(0–225)/72(0–288) n.s.
FC (-) vs. (+) 56/55 70(0–288)/69(0–273) n.s.
MIC (-) vs. (+) 81/30 64(0–279)/96(0–288) n.s.
TIMP-2
TC (-) vs. (+) 13/98 0(0–174)/80(0–288) 0.01
FC (-) vs. (+) 59/52 80(0–270)/63(0–288) n.s.
MIC (-) vs. (+) 63/48 80(0–288)/68.5(0–279) n.s.
TIMP-3
TC (-) vs. (+) 15/96 48(0–210)/76(0–288) n.s.
FC (-) vs. (+) 42/69 50.5(0–225)/88(0–288) n.s.
MIC (-) vs. (+) 53/58 64(0–279)/87(0–288) n.s.
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proliferation and the inhibition of apoptosis [37,38]. In a
prior report we found an increase in AR expression in the
transition from pure DCIS to DCIS adjacent to the inva-
sive component of breast carcinoma, which led us to con-
sider that there could be a relationship between both AR
and MMPs/TIMPs expression in breast carcinoma [39].
There are evidences indicating the existence of a steroid
regulation of the gelatinases (MMP -2 and MMP -9) in
both breast [40,41] and prostate cancer [42,43]. Likewise,
it is of note that the expression of MMP -13 (collagenase-
3), which has been associated with the microinvasive
component of "in situ" carcinomas [44], has been found
to be up-regulated by androgens in prostate cancer
derived the cell line LNCaP [23]. Nevertheless, the regula-
tion of MMPs production by androgens seems to be a
quite complex process. Thus, experimental studies
showed that androgens, via AR-Ets, negatively regulate the
expression of interstitial collagenase (MMP -1), stromeli-
sin-1 (MMP -3), and matrilysin -1 (MMP -7) [45]. Even so,
in despite of assuming an association between AR expres-
sion and some MMPs/TIMPs production in the context of
breast cancer, we could not determine any significant rela-
tionship between AR status and the occurrence of distant
metastases. This may be due to the consideration of the
cellular type expressing each factor in the tumor scene. In
accordance with other authors, we found that AR immu-
noreactivity is localized in the nuclei of tumor cells and
no stromal staining was observed [1,13]. However, there
is a biological variability with regard to the cellular type
expressing MMPs or TIMPs (cancerous cells and/or stro-
mal cells -fibroblasts or mononuclear inflammatory cells-
). When we considered this morphological aspect, we
found that AR-positive tumors had a higher percentage of
cases positive for MMP-1, -7, -11, and TIMP-2 in their
malignant cells, when compared to AR-negative tumors.
The only association with AR-positive status in stromal
cells was for MMP-1 in intratumor fibroblasts. We believe
that these findings could explain our results pointing the
lack of any significant association between AR status and
the occurrence of distant metastases because, such as it
was recently reported from our group, the expression of
these MMPs and the TIMP-2 correlate with distant metas-
tases mainly when those are expressed by stromal cells
[15,28]. Thus, our results led us to consider the existence
of a regulation of MMPs/TIMPs expression via AR in the
same tumor cells, but without a significant influence in
the development of distant metastases. We considered
that both AR and MMPs/TIMPs expression could be more
important in the early phases of tumor progression, but
less in primary invasive breast carcinomas.
On the other hand, our data demonstrated that the AR sta-
tus correlates significantly and independently with overall
patient survival. Other authors have also found that breast
cancer patients with AR-negative tumors show a trend
toward a shorter overall survival than those patients with
AR-positive tumors [24]. It has been proposed that this
trend may be secondary to the AR-positive tumors' capa-
bility to retain a hormone-sensibility that confers a low
biological aggressiveness. In fact, among the steroid hor-
mone receptors, AR is the best preserved one during
metastases development and is expressed in the majority
of metastatic tumors [21]. Furthermore, the effects of
tamoxifen [46] and medroxyprogesterone acetate are
mediated by AR [47]. A recent study showed that reduced
levels of AR or impaired AR function contribute to the fail-
ure of medroxyprogesterone acetate therapy, potentially
due to the abrogation of the inhibitory effect of AR on ER
signaling [48]. In addition, Aggof et al. have reported a
significant association in the univariate analysis (p =
0.049) between AR expression and relapse-free survival in
patients with ER-negative tumors (n = 57), but none with
overall survival [16]. In the present study we did not find
this association. Nevertheless, there are possible explana-
tions for that discrepancy with our results due to differ-
ences in the studied patient populations. Thus, although
we have a similar number of patients with ER-negative
tumors (n = 59), it is of note that our study included a
higher number of events (tumor relapses) (61%) than in
the study of Aggof et al, (33%), because our population
was selected stratifying on the basis of the occurrence of
distant metastases. Likewise, in our study we applied dif-
ferent criteria for patient selection, such as ductal being
the chosen histological type, considering distant metas-
Relapse-free survival and overall survival as a function of AR values in 111 breast c rcinomasFigur  3
Relapse-free survival and overall survival as a func-
tion of AR values in 111 breast carcinomas.Page 8 of 10
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only T1 and T2 tumors. On the other hand it is remarkable
that Schippinger et al., did not find in their multivariate
analysis any independent prognostic value for AR-expres-
sion in patients with metastatic breast cancer [25]. Never-
theless, this patient population differs clinically of that of
non-metastatic breast cancer included in our study. Even
so, the latter finding seems to indicate that the prognostic
significance of AR status may be lost once distant meta-
static disease occurs.
Conclusion
Our results confirm that AR are commonly expressed in
breast cancer, and correlate with the expression of some
MMPs and TIMP-2. Although we found a value of AR
expression to be a prognostic indicator in breast cancer,
the functional role of AR in these neoplasms is still
unclear and further data are needed to determine their
biological signification in breast cancer, i.e. if AR could be
used as a marker for efficiency of endocrine therapy and
for new hormonal therapeutic strategies in women with
ER-negative carcinomas, as well as on the prognostic sig-
nification of AR microsatellites polymorphism in breast
cancer, which could affect the transactivation capacity of
the receptor [49], and whether or not patients with ER-
negative, PR-negative, but AR-positive cancers behave dif-
ferently from those with triple negative breast carcinomas.
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